Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression. - Abrate C; Brunotto V; Bossio SN; Boccardo S; Tosello Boari J; Caudana P; Hernandez L; Gimenez C; Theumer MG; Sedlik C; Amezcua-Vesely MC; Robson SC; et al. (Frontiers in immunology, 2026)